COMP <GO>
CAI vs HSIC // 10Y YIELD & FRED MACRO BETA
Caris Life Sciences Inc. (NASDAQ) VS. Henry Schein Inc. (NASDAQ) • 15-METRIC TALLY: CAI 8
— HSIC 4
▲ 10Y YIELD & FRED MACRO BETA LEADER: CAI
LAST: $32.10 (-6.50%) • MKT CAP: $9.70B
macro-sensitivity
0.91
LAST: $86.62 (+2.05%) • MKT CAP: $9.46B
macro-sensitivity
0.89
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CAI VS. HSIC)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CAI | HSIC | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 31.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.40% | 11.20% | -6.80 | HSIC | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 9.5x | +85.50 | HSIC | /valuation <GO> |
| Free Cash Flow Yield | 0.65% | 1.23% | -0.58 | HSIC | /fcf-yield <GO> |
| Operating Margin | 5.60% | 5.00% | +0.60 | CAI | /operating-margins <GO> |
| Net Profit Margin | -8.40% | 3.20% | -11.60 | HSIC | /net-margins <GO> |
| Revenue Growth (YoY) | 97.00% | 4.00% | +93.00 | CAI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 9.79 | 2.81 | +6.98 | CAI | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | CAI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.8 | 47.5 | +11.30 | CAI | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.91 | 0.89 | +0.02 | CAI | /macro-sensitivity <GO> |
| Forward P/E Multiple | 21.0x | 21.4x | -0.40 | CAI | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.70B | $9.46B | $241.9M | CAI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CAI REV | HSIC REV | CAI GROSS % | HSIC GROSS % | CAI FCF | HSIC FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $812.0M | $13.18B | — | 31.1% | $66.9M | $118.7M |
| FY 2024 | $412.3M | $12.67B | — | 31.7% | -$253.6M | $277.7M |
| FY 2023 | $306.1M | $12.34B | — | — | -$289.9M | -$55.3M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CAI // BETA 0.91
HSIC // BETA 0.89